0000950170-24-075075.txt : 20240618
0000950170-24-075075.hdr.sgml : 20240618
20240618175942
ACCESSION NUMBER: 0000950170-24-075075
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240614
FILED AS OF DATE: 20240618
DATE AS OF CHANGE: 20240618
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moran Sean F.
CENTRAL INDEX KEY: 0001451495
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37348
FILM NUMBER: 241053376
MAIL ADDRESS:
STREET 1: 10220-L OLD COLUMBIA ROAD
CITY: COLUMBIA
STATE: MD
ZIP: 21046
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Corbus Pharmaceuticals Holdings, Inc.
CENTRAL INDEX KEY: 0001595097
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464348039
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 RIVER RIDGE DRIVE
CITY: NORWOOD
STATE: MA
ZIP: 02062
BUSINESS PHONE: 617-963-0103
MAIL ADDRESS:
STREET 1: 500 RIVER RIDGE DRIVE
CITY: NORWOOD
STATE: MA
ZIP: 02062
FORMER COMPANY:
FORMER CONFORMED NAME: SAV Acquisition Corp
DATE OF NAME CHANGE: 20131220
4
1
ownership.xml
4
X0508
4
2024-06-14
0001595097
Corbus Pharmaceuticals Holdings, Inc.
CRBP
0001451495
Moran Sean F.
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC
500 RIVER RIDGE DRIVE
NORWOOD
MA
02062
false
true
false
false
Chief Financial Officer
true
Common Stock, par value $0.0001 per share
2024-06-14
4
M
false
1567
30
A
50172
D
Common Stock, par value $0.0001 per share
2024-06-14
4
S
false
1567
49.8738
D
48605
D
Common Stock, par value $0.0001 per share
2024-06-14
4
M
false
7788
4.26
A
56393
D
Common Stock, par value $0.0001 per share
2024-06-14
4
S
false
7788
49.8738
D
48605
D
Common Stock, par value $0.0001 per share
2024-06-17
4
M
false
6730
14.10
A
55335
D
Common Stock, par value $0.0001 per share
2024-06-17
4
S
false
6730
46.774
D
48605
D
Common Stock, par value $0.0001 per share
2024-06-18
4
M
false
1958
30
A
50563
D
Common Stock, par value $0.0001 per share
2024-06-18
4
S
false
1958
42.1242
D
48605
D
Options to purchase common stock
30
2024-06-14
4
M
false
1567
0
D
2024-10-22
Common Stock
1567
1958
D
Options to purchase common stock
4.26
2024-06-14
4
M
false
7788
0
D
2024-02-13
2033-02-13
Common Stock
7788
23367
D
Options to purchase common stock
14.10
2024-06-17
4
M
false
6730
0
D
2023-02-01
2032-02-01
Common Stock
6730
11217
D
Options to purchase common stock
30
2024-06-18
4
M
false
1958
0
D
2024-10-22
Common Stock
1958
0
D
This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $49.47 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $43.59 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.
The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023.
/s/Sean Moran
2024-06-18